On the other hand, cotreatment of CML cells with JNJ-165 and the protein synthesis inhibitor cycloheximide (CHX) depleted the levels of BCR/ABL. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.